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Abstract: Patients undergoing arthroplasty or other orthopedic surgery show a high risk of 
venous thromboembolism (VTE), involving mortality, morbidity, and social costs; however, 
the risk for VTE in minor orthopedic surgery should not be underestimated and antithrombotic 
prophylaxis may be required. According to the literature, low-molecular-weight heparins 
(LMWHs) are more effective in preventing VTE than unfractionated heparins (UFHs) or 
vitamin K antagonists, and have a lower hemorrhagic risk. By comparing different prophylactic 
regimens, it has been shown that starting the prophylaxis near the time of the operation 
is the most critical point for efﬁ  cacy, whether or not the ﬁ  rst dose is administered pre- or 
post-operatively. Moreover, most thromboembolic complications are observed after discharge 
and, therefore, many clinicians advocate continuing prophylaxis for longer times (6–8 weeks) 
in order to further reduce the rate for VTE. The literature on parnaparin, a new LMWH, in VTE 
prophylaxis was reviewed. Parnaparin is equally effective as UFH, but it offers the advantages 
of a once-daily administration and improved tolerability, thus allowing the home management 
of patients with no need for laboratory coagulation tests.
Keywords: orthopedic surgery, low molecular weight heparins, antithromboembolic 
prophylaxis, parnaparin
Prophylaxis of venous thromboembolism
Patients undergoing elective arthroplasty (hip or knee) or other major orthopedic 
surgery are at high risk of developing venous thromboembolism (VTE), which repre-
sents a dangerous event in terms of mortality and morbidity with high social impact 
and costs.
Randomized clinical trials (RCT) estimate that, in absence of a thromboprophy-
laxis, the incidence of venographically proven VTE ranges from 45% to 57% after 
total hip replacement (THR) surgery, 36% to 60% after hip fracture surgery (HFS), 
and 40% to 84% after total knee replacement (TKR) surgery (Geerts et al 2001; Geerts 
et al 2004).
Although low-dose unfractionated heparin (UFH) (Collins et al 1988) and aspirin 
(Antiplatelet Trialists’ Collaboration 1994) have been reported more effective than 
no prophylaxis in patients undergoing THR, these agents have been abandoned today 
in favor of low-molecular-weight heparins (LMWHs), vitamin K antagonists, and 
synthetic derivatives of factor Xa inhibitor, such as fondaparinux.
In fact, several studies (Chiapuzzo et al 1988; Mascali et al 1988; Planes et al 
1988; Pini et al 1989; German Hip Arthroplasty Trial Group 1992; Colwell et al 1994; 
Haas et al 2006) and meta-analyses (Nurmohamed et al 1992; Freedman et al 2000; 
Koch et al 2001) have conﬁ  rmed that LMWHs are more effective than low-dose or 
adjusted-dose UFH with a relative risk reduction of 25%–50%. Moreover, LMWH 
are as effective as vitamin K antagonists in the TVE prevention, but they have a lower 
hemorrhagic risk (Imperiale and Speroff 1994; Palmer et al 1997; Fitzgerald et al 2001; Vascular Health and Risk Management 2008:4(5) 984
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Samama et al 2002; Bandiera et al 2003; Haas et al 2006; 
Prejbeanu et al 2007).
While the phophylactic efficacy of LMWH is today 
unquestioned, the treatment schedule (when to begin, how 
many times a day, and for how long) is a still debated point.
The standard protocols in North America recommend 
the administration of a ﬁ  rst LMWH dose between 12 and 
24 hours after surgery, whereas in Europe the prophylaxis 
is often begun pre-operatively (10–12 hours before surgery) 
(Strebel et al 2002). Several authors have compared different 
prophylactic regimens in order to ascertain whether the ﬁ  rst 
dose is more effective if given pre- or post-operatively. It has 
been shown that starting the prophylaxis near the time of the 
operation is the most critical point, whether or not the ﬁ  rst 
dose is administered pre- or post-operatively (Laguardia and 
Caroli 1992; Strebel et al 2002; Bandiera et al 2003; Raskob 
and Hirsh 2003). A review of RCTs has shown a reduction 
of 40%–50% in the DVT rate in THR patients when the 
prophylaxis was begun between 2 hours before and 8 hours 
after surgery, although the pre-operative administration of 
heparin seemed to involve a higher hemorrhagic risk (Hull 
et al 2001). The risk can be reduced, however, by giving an 
early post-operative (6–8 hours) low dose of heparin, and 
by increasing the doses of heparin in the following 24 hours 
or later, according to the course of post-operative bleeding 
(Hull et al 2000; Geerts et al 2004).
On the other hand, the risk for TVE is not conﬁ  ned to 
the immediate post-operative period. According to litera-
ture, most of symptomatic TVE complications (12%–35%) 
occur after discharge; thus, several authors suggest that the 
prophylactic treatment should be continued for longer times 
(6–8 weeks) whenever risk factors are present, and be stopped 
only when full weight on the treated limb is resumed. It has 
been reported that continuation of prophylaxis for at least 
2 weeks may further reduce the TVE risk by an additional 
50% (White et al 1998; Samama et al 2002; Geerts et al 
2004; Goldhaber 2004; Verhaeghe 2005; Arcelus et al 2006; 
Prejabeanu et al 2007).
Finally, the risk for TVE in minor orthopedic surgery 
should not be underestimated even if an antithromboembolic 
prophylaxis is rarely used in these patients. The presence of 
concomitant risk factors for thromboembolism, as well as the 
frequent use of a tourniquet with subsequent revasculariza-
tion in performing these operations, may explain the high 
rate of TVE complications in this “minor” surgery. Thus, 
appropriately long prophylaxis with LMWH is also indicated 
in these patients (Obermosterer et al 1999; Michot et al 2002; 
Montebugnoli et al 2007).
Low-molecular-weight heparins
LMWHs are extracted from UFH of animal origin with 
a molecular weight (MW) ranging between 4,000 and 
30,000 Da. The activity of LMWHs is mediated by their 
binding to antithrombin III (AT III); however, because of 
fragmentation, the coagulation factors IIa and Xa are affected 
differently by AT III and, therefore, the antithrombotic 
activity is separated by the anticoagulant effect because of a 
larger anti-Xa activity compared with anti-IIa activity.
The structural changes in LMWHs modify the phar-
macokinetics compared with UFH: the absorption after 
subcutaneous (sc) administration is almost complete, pre-
dictable, and reliable. The smaller molecules have a lower 
binding to plasma and tissue proteins and, consequently, a 
higher antithrombotic activity is available in the plasma; 
moreover, LMWHs undergo reduced liver metabolism and 
have an increased renal elimination. The plasma half-life of 
LMWHs is therefore longer than that of UFH, although to 
varying degrees among different molecules, thus allowing 
for a single daily administration.
The anti-Xa/anti-IIa activity rate expresses the relation-
ship between the doses producing the desired antithrombotic 
activity, and those producing the undesired anticoagulant 
effects. This way of expressing the activity of the LMWH 
has a clinical meaning during DVT prophylaxis, the main 
objective of prophylaxis being to inhibit the formation 
and growth of ﬁ  brin thrombus at the site of DVT without 
affecting the systemic coagulation. It is generally recognized 
that the greater is the fractioning of the AT III-binding chain, 
the shorter and more homogeneous the synthetic molecule, 
and the more selective the inhibitory activity on factor Xa 
compared with factor IIa.
Parnaparin
Our aim was to review the available clinical data on 
parnaparin, a LMWH that is effective and generally well 
tolerated in the prevention of VTE, as well as in the treat-
ment of arterial and venous diseases (McKeage and Keating 
2008). The data source was PubMed, which was searched 
for “parnaparin” or “Fluxum”, returning 4 reviews and 25 
experimental works; no restriction on language and time was 
applied. Moreover, published reports not listed in PubMed 
were provided by Alfa Wassermann S.p.A. (Bologna, Italy). 
Dosages of parnaparin reported in this review (3,200, 6,400 
and 12,800 IUaXa) were calculated using the chromogenic 
method from the European Pharmacopoea Standard of 
LMWH. These units are equivalent to those mentioned in 
clinical papers from the 1980s through to the mid 1990s Vascular Health and Risk Management 2008:4(5) 985
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(7,500, 15,000, and 30,000 aXaU), which were calculated 
using the chromogenic method from the 4th International 
Standard of Unfractionated Heparin.
Pharmacology and pharmacokinetics
Parnaparin is a LMWH obtained with an original and pat-
ented procedure of fragmentation, which guarantees the 
homogeneity of fragments in terms of molecular weifht; 
thus, all the fragments have the right length to optimize the 
dissociation between the antithrombotic and anticoagulant 
activities (anti-Xa/anti-IIa ratio 4).
The most interesting characteristics of parnaparin are its 
speed of action after sc administration (Tmax ≈ 3 hours) and its 
plasma half-life (about 6 hours), which are ideal for a single 
daily administration (Summary of Product Characteristics 
approved by Regulatory Authorities); therefore, parnaparin 
provides a rapid antithrombotic protection in urgent situa-
tions, and it has a minimal risk for drug accumulation and 
consequent hemorrhagic risk (Table 1).
In principle, the predictable and constant pharmacokinetics 
of parnaparin makes its use much easier and simpler in 
day-by-day clinical practice; moreover, like other LMWHs, 
the low inﬂ  uence of parnaparin on coagulation means that 
repeated lab tests are not needed monitor coagulation times. 
The consequent practical advantage is a simpler management 
of post-operative DVT prophylaxis at home.
Experimental observations show the ability of 
parnaparin to prevent in vitro the activation of platelets 
and leukocytes, and to inhibit the formation of leukocyte-
platelet aggregates (Maugeri et al 2005; Ludwig et al 2006; 
Maugeri et al 2007).
The neutralization of parnaparin by protamine chloride 
has been studied in vitro on coagulation tests (APTT, anti-Xa 
activity). The activity of parnaparin on APTT has been com-
pletely neutralized by protamine with a parnaparin/protamine 
ratio of IUaXa/20 μg, whereas anti-Xa activity has been 
partially but substantially neutralized by protamine (Milani 
and Palazzini 1990).
Parnaparin in major orthopedic surgery
Clinical evidence for the effectiveness of LMWH and, espe-
cially, of parnaparin, in the prevention of DVT in patients 
undergoing major orthopedic surgery for arthroplasty and 
trauma has been published over several years. Prophylaxis 
with parnaparin has been reported to be more effective than 
placebo (Valle et al 1988) and more advantageous than UFH. 
In a series of 140 patients, DVT was detected in legs either 
by Doppler sonography or 125I-ﬁ  brinogen uptake test in 7.1% 
and 10% of patients treated, respectively, with parnaparin 
3,200 IUaXa sc (= 7,500 aXaU) twice daily or calcium UFH 
5,000 IU sc 3 times daily, given for 7 days (Chiappuzzo et al 
1988). In another trial aimed at preventing post-operative 
VTE after hip fracture, 49 patients were randomly treated 
either with parnaparin 3,200 IUaXa twice daily or with UFH 
5,000 IU tid. Screening for thrombosis was performed with 
125I-ﬁ  brinogen leg scanning and strain-gauge plethysmog-
raphy, and positive results were conﬁ  rmed by venography. 
In this study, the rate of venographically proven DVT was 
20% in the parnaparin group and 29% in the UFH group. The 
difference was not statistically signiﬁ  cant since the number 
of randomized patients was rather small, but there was an 
interesting trend in favor of parnaparin, as 1 pulmonary 
embolism and 2 deaths occurred in the UFH group, and none 
in the parnaparin group (Pini et al 1989).
Bandiera et al (2003) performed a multicenter study on 
381 patients at high risk of DVT undergoing major orthopedic 
surgery; they were treated with UFH, parnaparin or other 
LMWHs, given around the time of surgery and continued at 
home for 10–90 days according to the type of operation or 
risk factors. Parnaparin was administed once daily at doses 
ranging between 3,200 and 4,250 IUaXa/day. DVT was diag-
nosed clinically and instrumentally (Echo Color Doppler). 
The authors concluded that LMWHs were signiﬁ  cantly more 
effective than UFH (DVT rate 10.3% vs 16.6%), and that 
parnaparin was even slightly more effective (DVT 8.4%) 
than other LMWHs, although a signiﬁ  cant difference was 
not achieved (Table 2).
Moreover, while one case of major bleeding was observed 
for each treatment groups (ie, UFH, parnaparin and other 
LMWH), episodes of minor bleeding (such as a local hema-
toma at the site of injection or surgical wound or a need for 
a surgical drainage) were observed in 17.85%, 6.06%, and 
11.76%, respectively, of UFH, parnaparin, and other LMWH-
treated patients. Other adverse drug reactions (ADRs) 
Table 1 Pharmacokinetic parameters of unfractionated heparins 
and low-molecular-weight heparins
Absorption Tmax t½ Anti-Xa/
Anti-IIa
Sodium UFH 15%–30% 3 hours 1 hour 1
Tinzaparin 90% 4–6 hours 1.5 hours 1.5
Dalteparin 90% 3–4 hours 4 hours 2.6
Reviparin 95% 3–4 hours 3 hours 3.5
Enoxaparin 100% 3 hours 4.4 hours 4
Nadroparin 98% 4–6 hours 8–10 hours 4
Parnaparin 90% 3 hours 6 hours 4Vascular Health and Risk Management 2008:4(5) 986
Bugamelli et al
(such as pain or irritation at the injection site), were observed 
in 25.0%, 7.4%, and 32.4% of patients treated, respectively, 
with UFH, parnaparin, and other LMWHs (Table 3).
The slightly higher antithrombotic activity achieved with 
parnaparin and other LMWHs compared with UFH demon-
strates that a higher level of inhibition of Xa is associated 
with administration of a LMWH with no increase hemor-
rhagic risk. Thus, the use of parnaparin appears to be safer in 
orthopedic prophylaxis, as suggested by Mascali et al (1988), 
who reported a statistically signiﬁ  cant lower incidence of 
side effects (ie, local hematomas) in parnaparin- than in 
UFH-treated patients (25.0% vs 64.7%).
The more appropriate time for starting prophylaxis with 
parnaparin was investigated by Laguardia and Caroli (1992). 
Forty patients undergoing THR were randomly treated with 
parnaparin 6,400 IUaXa in once-daily administration starting 
either 2 hours before or 2 hours after the surgical operation. 
The treatment lasted 7 days. The results showed that the 
incidence of DVT was very similar and extremely low in 
the two groups, only 1 patient in each group having a posi-
tive diagnosis on phlebography. Although the sample size 
was relatively small, the authors concluded that prophylaxis 
was effective in both groups with a DVT rate approaching 
5%, and without any signiﬁ  cant difference between groups 
in the amount of perioperative bleeding.
Parnaparin in minor orthopedic surgery
Over the past 20 years, arthroscopy has become an important 
tool in orthopedics for virtually every joint. Complication 
rates for arthroscopy are low but not absent (8.2%), 
including DVT and PE, whose incidence may be increased 
either by speciﬁ  c risk factors of patients (such as old age, 
obesity, and concomitant venous diseases) or by the local 
ischemia secondary to the use of a tourniquet (Table 4). Thus, 
the need for prophylaxis in minor orthopedic surgery should 
not be undervalued (Poulsen et al 1993; Eynon et al 2004; 
Navarro-Sanz and Fernandez-Ortega 2004).
Clinical studies show that adequate prophylaxis can be 
achieved with LMWHs (Table 5).
In order to obtain information about the efﬁ  cacy and 
safety of parnaparin in minor orthopedic surgery under 
tourniquet ischemia, we have identiﬁ  ed prospectively 509 
patients in our center. Knee arthroscopy represented the most 
frequent surgery (68% of the survey), followed by removal of 
a ﬁ  xation device or other foreign material (14%), foot surgery 
(8.1%), arthroscopy of the ankle and shoulder (1.6%), biopsy 
(5.1%), and other surgery (3.3%).
The antithromboembolic prophylaxis with once-daily 
parnaparin (3,200–4,250 IUaXa) was initiated within 6 hours 
after the end of surgery and extended until full weight bearing 
and walking was resumed (10.5 ± 9.1 days). All the patients 
underwent compression ultrasound on days 8 to 10 or with 
the onset of clinical signs suggesting DVT. Instrumental tests 
never revealed proximal DVT, while minor bleeding (hema-
toma in surgical site with hemoglobin decrease 2 g/dL) was 
found in 7 cases (1.4%) (Montebugnoli et al 2007).
Other uses of parnaparin
Parnaparin has been also employed for TVE prophylaxis 
in non-orthopedic surgery. A multicenter study performed 
by Verardi et al (1988) on 610 patients undergoing general 
(mainly abdominal) surgery, a statistically signiﬁ  cant differ-
ence was observed between parnaparin 3,200–6,400 IUaXa 
once daily and UFH in the rate of post-operative DVT (3.2% 
vs 6.3%; p  0.01), although the difference in the incidence 
of PE between treatment groups did not reach signiﬁ  cance 
(0.3 vs 1.0%).
Parnaparin has been used for VTE prophylaxis in 
bariatric surgery. Ten severely obese patients (body mass 
index 50 kg/m²) have been treated with increasing single 
daily doses of parnaparin (3,200, 4,250, and 6,400 IUaXa) on 
the three consecutive days leading up to biliointestinal bypass 
surgery. The highest dose was continued from the day of sur-
gery until day 30 (recovery period). During the pre-operative 
Table 2 Rate of deep vein thrombosis in patients who underwent 
surgery for total hip replacment
No. patients No. DVT
UFH 12 2 (16.67%)
Other LMWHs 29 3 (10.34%)
RRa vs UFH 0.624 (0.098–1.148)
Parnaparin 59 5 (8.47%)
RR vs UFH 0.463 (0.079–2.727)
RR vs other LMWHs 0.832 (0.224–1.756)
aOdds ratios (RR) were calculated with the 95% conﬁ  dence limits with reference to 
UFH (Bandiera et al 2003).
Abbreviations: DVT, deep vein thrombosis; LMWH, low-molecular-weight heparins; 
UFH, unfractionated heparins.
Table 3 Rate of major and minor bleeding and other adverse drug 
reactions (ADR) observed with unfractionated heparins, parnaparin 
and other low-molecular-weight heparins (Bandiera et al 2003)
No. 
patients
No. major 
bleedings
No. minor 
bleedings
No. other 
ADRS
UFH 28 1 (3.57%) 5 (17.85%) 7 (25.00%)
Parnaparin 231 1 (0.43%) 14 (6.06%) 17 (7.36%)
Other LMWHs 102 1 (0.98%) 12 (11.76%) 33 (32.35%)
Abbreviations: ADRS, artificial disc replacement surgery; LMWH, low-
molecular-weight heparins; UFH, unfractionated heparins.Vascular Health and Risk Management 2008:4(5) 987
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dosing phase, parnaparin dose-dependently prolonged APTT, 
with the 6,400 IUaXa dose signiﬁ  cantly prolonging aPTT 
vs the lower doses. Meanwhile, the 4,250 and 6,400 IUaXa 
once-daily doses increased anti-factor Xa and anti-factor 
IIa activity. After surgery, 1 patient with heparin resistance 
experienced pulmonary embolization. No bleeding complica-
tions were observed. The dose-response data reported in this 
preliminary study suggest that parnaparin doses of 4,250 and 
6,400 IUaXa may provide effective prophylaxis for VTE in 
patients undergoing bariatric surgery. However, given the 
small number of patients, larger, well-controlled trials are 
required to conﬁ  rm these ﬁ  ndings (Forestieri et al 2007).
Bellosta et al (2007) have compared the effectiveness 
of nadroparin and parnaparin in the non-prophylactic treat-
ment of DVT in terms of the evolution of thrombosis, in a 
randomized prospective study in 91 patients. Overall, there 
were 3 cases (3.3%) of progression of thrombosis despite 
therapy with LMWH, 2 cases (5%) in the nadroparin group, 
and 1 case (2%) in the parnaparin group (not signiﬁ  cant). 
The Doppler ultrasound in the follow-up showed a complete 
resolution of 56% of DVT at an average of 6.1 ± 4.6 months. 
Valve competence recovered in 65.9% of cases with no 
signiﬁ  cant difference between the two groups.
Parnaparin has been successfully used in the treatment 
of coronary artery diseases (CAD). Parnaparin 6,400 IUaXa 
once daily sc for 7 days was more effective than UFH given 
intravenously for 48 hours, then sc (UFH 5,000 IU every 
6 hours) for 5 days in a randomized, multicenter study in 
patients (n = 897) with unstable angina. The incidence of 
the triple composite endpoint (death, acute myocardial 
infarction [MI] or the need for myocardial revascularizations 
in the 7 days after the start of treatment) was signiﬁ  cantly 
lower in the parnaparin than in the UFH group (7% vs 11%; 
p = 0.034) (Prime Care Study 2005).
Similarly, in patients with an acute STEMI, sc parnaparin 
4,250 IUaXa every 12 hours for 7 days was associated with 
a lower incidence of a triple composite endpoint of death, 
acute MI, or the need for myocardial revascularization in 
the 45 days after the start of treatment than intravenous 
UFH administered for 3 days followed by subcutaneous 
UFH 7,500 IU every 12 hours for 4 days (27% vs 42%; 
p = 0.03) (Wang et al 2006). Moreover, in patients with stable 
Table 4 Prospective uncontrolled trials, without heparin prophylaxis, in knee arthroscopy using objective methods for detecting deep 
vein thrombosis
Study No. patients Diagnosis method Rate of venous thrombosis (no./%)
Stringer et al (1989) 48 Venography 2 4.2%
Williams et al (1995) 85 Compression ultrasonography 3 3.5%
Cullison et al (1996) 67 Compression ultrasonography 1 1.5%
Durica et al (1997) 190 Venography 6 3.2%
Demers et al (1998) 184 Venography 33 17.9%
Jaureguito et al (1999) 239 Venography 7 2.9%
Wirth et al (2001) 117 Venography 5 4.3%
Delis et al (2001) 102 Color Duplex 8 7.41%
Total 1,032 65 6.29%
Adapted with permission from Wirth T, Schneider B, Misselwitz F, et al. 2001. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight 
heparin (reviparin): results of a randomized, controlled trial.   Arthroscopy, 17:393–9. Copyright © Elsevier Ltd, and reproduced with permission from Montebugnoli M, 
Bugamelli S, Zangheri E, et al. 2007. Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin. Clin Appl  Thromb Hemost, 13:249–58. Copyright © 
Sage publications.
Table 5 Rate of deep vein thrombosis in patients undergoing knee arthroscopy and receiving different low-molecular-weight heparin 
prophylactic treatment (revision of the literature)
LMWH Dose (IU/die) Study No. patients Diagnostic method DVT rate (No./%)
Reviparin 1,750 Wirth et al (2001) 116 Eco-color Doppler 1/0.86%
Dalteparin 2,500–5,000 Michot et al (2002) 66 Compression ultrasound 1/1.52%
Dalteparin 5,000 Schippinger et al (1998) 101 Duplex ultrasound 12/11.88%
Nandroparin 3,075 Holland and Schain (1995) 101 Unknown 5/4.95%
Parnaparin 3,200–4,250 Montebugnoli et al (2007) 509 Compression ultrasound 0/0.00%
Abbreviations: DVT, deep vein thrombosis; LMWH, low-molecular-weight heparins; UFH, unfractionated heparins.Vascular Health and Risk Management 2008:4(5) 988
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angina, parnaparin 6,400 IUaXa once daily, together with 
conventional therapy, signiﬁ  cantly increased exercise time 
compared with placebo (Melandri et al 1993).
Finally, in patients with peripheral arterial obstructive 
disease a long-term treatment (6–8 months) with parnaparin 
6,400 IUaXa once daily sc significantly improved the 
pain-free walking time/distance compared with baseline in 
several studies (Palmieri et al 1988; Mannarino et al 1991; 
Calabro et al 1993; Simoni et al 1993). The extent of 
improvement with parnaparin was similar to that demonstrated 
with UFH in one study (Di Stefano et al 1988).
Tolerability of parnaparin
In humans, a higher rate of post-operative bleeding has been 
observed to related closely to the dose administered: at a pro-
phylactic dose (3,200–6,400 IUaXa/day) the risk of bleeding 
is statistically not signiﬁ  cant, and in any case lower than 
that observed with UFH (Martines et al 1990; Bandiera et al 
2003). LMWHs do not cross the human placenta and are not 
detected in fetal blood during the ﬁ  rst 6 months of pregnancy 
(Forestier et al 1984; Ostergaard et al 1989); therefore, they 
are also safe in pregnant women (Geerts et al 2004; Desai 
and Suk 2007). Although rare episodes of immunomediated 
thrombocytopenia due to the use of other LMWHs have 
been reported (Lecompte et al 1991; Mohr and Lenz 1991), 
thrombocytopenia related to the use of parnaparin has not 
yet been observed.
At a local level, the tolerability of parnaparin seems better 
than that of UFH, with a lower rate of hematomas, pain, and 
burning in the injection site (Corrado et al 1989; Verardi et al 
1989; Mangialardi et al 1991; Della Marchina et al 1993; 
Bandiera et al 2003; Bellosta et al 2007).
Conclusions
A review of the literature shows that parnaparin, like other 
LMWHs, is effective and well tolerated when used for 
prophylaxis of post-operative VTE in orthopedic surgery. 
Its effectiveness seems to be far superior to that of UFH, 
and comparable with other LMWHs when initiated pre- or 
post-operatively near the time of surgery and continued at 
home for a period depending on the type of operation. Besides 
the clinical advantages, parnaparin and other LMWHs 
enable a simpler home management of the prophylaxis since 
they can be administered once a day and do not require 
continuous lab tests.
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